S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPY
8. SPGI
9. RIVN
10. AGIO

Go back to S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook

Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral

November 10, 2016 8:04 AM EST

Rodman & Renshaw downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral with a price target of $23.00 (from $81.00). The change follows its Q3 revenue and earnings miss.

Analyst Raghuram Selvaraju said, "In its financial results for 3Q16 reported earlier this week, Valeant reported adjusted... More

Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook Negative

November 8, 2016 2:14 PM EST

Moody's Investors Service downgraded the ratings of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and subsidiaries, including the Corporate Family Rating to B3 from B2 and the Probability of Default Rating to B3-PD from B2-PD. Other downgrades include the senior secured bank credit facilities to Ba3 (LGD 2) from Ba2 (LGD 2) and senior unsecured debt to Caa1 (LGD 5) from B3 (LGD 5). At the same time, Moody's affirmed Valeant's SGL-3 Speculative Grade Liquidity Rating. The rating outlook is negative.

The downgrade reflects Valeant's challenges in turning around its specialty pharmaceuticals business, resulting in weak... More